北京同仁堂股份有限公司 2023年半年度报告 公司代码：600085 公司简称：同仁堂 北京同仁堂股份有限公司 2023 年半年度报告 ...

证券代码：600085 证券简称：同仁堂 公告编号：2023-030 北京同仁堂股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召开的时间、地点 召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 召开方式：网络文字互动 1 会议召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 会议召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 会议召开方式：网络文字互动 三、 参加人员 重要内容提示： 投资者可以在 2023 年 9 月 4 日下午 16:00 前将需要了解的情况和关注问题预 先发送到北京同仁堂股份有限公司（以下简称公司）邮箱，公司将在说明会上就 投资者普遍关注的问题进行回答。 公司于 2023 年 8 月 30 日披露了《2023 年半年度报告》，为便于广大投资 ...

2023年第一季度报告 证券代码：600085 证券简称：同仁堂 北京同仁堂股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 ...

Financial Performance - The company's operating revenue for 2022 was CNY 15,372,423,363.17, representing a 5.27% increase from CNY 14,603,100,739.78 in 2021[19] - The net profit attributable to shareholders of the listed company for 2022 was CNY 1,425,811,705.31, an increase of 16.17% compared to CNY 1,227,372,820.22 in 2021[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,398,575,430.62, up 15.67% from CNY 1,209,084,450.63 in the previous year[19] - Basic earnings per share rose by 16.20% to CNY 1.040 in 2022 compared to CNY 0.895 in 2021[20] - The weighted average return on equity increased by 0.72 percentage points to 12.71% in 2022 from 11.99% in 2021[20] - The gross profit margin improved to 48.80%, up by 1.18 percentage points compared to the previous year[32] - The total pre-tax compensation for the board members amounted to 1,067.37 million CNY for the reporting period[104] Cash Flow and Assets - The net cash flow from operating activities was CNY 3,094,296,284.27, a decrease of 9.69% from CNY 3,426,414,563.66 in 2021[19] - Total assets increased by 7.86% to CNY 27,044,491,889.50 in 2022 from CNY 25,072,835,362.31 in 2021[20] - The net cash flow from operating activities decreased by 9.69% year-on-year, amounting to 3,094.30 million yuan, mainly due to increased cash payments for goods and services[48] - The net increase in cash and cash equivalents was 1,735.40 million yuan, reflecting a 5.16% increase compared to the previous year[48] - Cash and cash equivalents amounted to ¥4,872,001,806.53 in 2022, an increase from ¥3,927,134,045.02 in 2021, marking a rise of about 24.0%[198] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 3.2 per 10 shares (including tax) based on a total share capital of 1,371,470,262 shares[4] - The company distributed a cash dividend of CNY 397,726,375.98, which accounts for 32.40% of the net profit attributable to ordinary shareholders in the consolidated financial statements[134] - The cash dividend per 10 shares is CNY 2.9, with no bonus shares or capital increase from reserves proposed[134] - The company has maintained a stable and continuous return policy for shareholders, considering future funding needs[132] Risk Management and Compliance - The company did not face any significant risks that could materially affect its operations during the reporting period[6] - The company has established a comprehensive integrity and compliance mechanism, including the formation of an Integrity and Compliance Committee and the implementation of risk assessment and feedback mechanisms[27] - The company emphasizes the importance of risk awareness regarding forward-looking statements in its report[5] - The company is facing risks related to industry policy changes, raw material supply fluctuations, and market instability, and is adapting its strategies accordingly[94] - The company is committed to maintaining high-quality standards in drug production and is enhancing its procurement processes to mitigate risks associated with raw material quality[94] Research and Development - Research and development expenses increased by 23.59% to CNY 217,446,263.51, indicating a significant investment in innovation[32] - The total R&D investment amounted to 3,660.83 million yuan, representing 2.38% of operating revenue, with a year-on-year increase of 14.50%[44] - The R&D team has made progress in new product development, including classic formulas and quality standards, with a focus on enhancing product value and addressing resource scarcity issues[65] - The company is actively pursuing internationalization of traditional Chinese medicine, particularly in the Hong Kong market, by enhancing marketing reforms and multi-channel promotion[28] - The company is focused on enhancing its product portfolio through strategic R&D initiatives and exploring market opportunities[65] Market Expansion and Retail Strategy - The company plans to continue focusing on market expansion and new product development to drive future growth[20] - As of the end of the reporting period, the company had 942 retail stores, focusing on enhancing operational efficiency and new retail technology to improve overall service levels[25] - The company has expanded its retail network to 73 stores globally, covering major countries and regions in Asia, Oceania, North America, and Europe[28] - The company is focusing on market demand and consumer trends, emphasizing marketing innovation and precise promotion strategies[57] Corporate Governance - The company has established an independent financial accounting department and a financial management system, ensuring independent financial decision-making[98] - The company’s management team is fully independent, with no overlapping positions with the controlling shareholder, ensuring transparency in personnel management[99] - The company’s governance structure includes various committees, such as the Strategic and Investment Committee and the Audit Committee, to ensure effective oversight[96] - The company has committed to enhancing its compliance management and legal support systems to foster a culture of integrity and compliance[99] Environmental Responsibility - The company has completed carbon emission verification and compliance tasks for 2021, demonstrating its commitment to environmental responsibility[27] - The company has invested CNY 20.84 million in environmental protection during the reporting period[142] - The company has achieved a total carbon emission of 20,516 tons for the year 2021, fulfilling its carbon emission quota in Beijing[153] - The company has implemented energy-saving management and new technologies to strengthen carbon emission management[155] Employee Development - The company emphasizes talent development through a diversified training system, focusing on management, professional technical, and high-skilled personnel[129] - The company has implemented a salary and assessment system for its management team to enhance performance motivation[136] - The company organizes annual continuing education training for professional technical personnel to strengthen their skills and knowledge[131] Shareholder Information - The total number of ordinary shareholders increased to 84,241 by the end of the reporting period, up from 77,597 at the end of the previous month[177] - The largest shareholder, China Beijing Tongrentang (Group) Co., Ltd., holds 719,308,540 shares, accounting for 52.45% of the total shares[178] - The company has no controlling shareholder or actual controller changes during the reporting period[182]

Financial Performance - In 2021, the company's operating revenue reached CNY 14,603,100,739.78, representing a year-on-year increase of 13.86% compared to CNY 12,825,879,050.96 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was CNY 1,227,372,820.22, an increase of 19.00% from CNY 1,031,440,914.95 in 2020[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,209,084,450.63, up 19.52% from CNY 1,011,615,144.02 in 2020[21] - The net cash flow from operating activities was CNY 3,426,414,563.66, a significant increase of 57.56% compared to CNY 2,174,631,663.93 in 2020[21] - As of the end of 2021, the total assets amounted to CNY 25,072,835,362.31, reflecting a growth of 14.82% from CNY 21,837,512,362.24 at the end of 2020[21] - The net assets attributable to shareholders of the listed company were CNY 10,633,965,371.99, an increase of 8.16% from CNY 9,831,569,428.09 at the end of 2020[21] - Basic earnings per share for 2021 increased by 19.02% to CNY 0.895 compared to CNY 0.752 in 2020[22] - The weighted average return on equity rose to 11.99%, an increase of 1.17 percentage points from 10.82% in 2020[22] - The comprehensive gross profit margin improved to 47.62%, an increase of 0.58 percentage points from the previous year[44] - The company reported a net profit margin of 9.68%, indicating strong profitability[134] Cash Flow and Investments - The net cash flow from operating activities increased by 57.56% to CNY 3,426,414,563.66 in 2021 from CNY 2,174,631,663.93 in 2020[62] - The net cash flow from investing activities improved, with cash outflows for fixed assets and intangible assets decreasing significantly[63] - The net cash flow from financing activities decreased, primarily due to increased cash payments for debt repayment by subsidiaries[63] - The net increase in cash and cash equivalents rose by 143.07% to CNY 1,650,272,492.17 in 2021 from CNY 678,917,148.70 in 2020[62] - The company reported a significant increase in investment income, rising to 9,343,298.96, a 1458.7% increase from the previous year[55] Revenue and Sales - Total operating revenue for Q4 2021 was CNY 3,919,917,415.37, with a net profit attributable to shareholders of CNY 307,374,143.31[24] - The total revenue for the first quarter of 2021 was CNY 3,706,471,529.65, with a net profit of CNY 318,415,643.66 attributable to shareholders[24] - The company achieved a revenue of 1,291.76 million yuan in 2021, representing a year-on-year growth of 10.37%[38] - Operating profit for the year was 645.35 million yuan, an increase of 5.02% compared to the previous year[38] - Net profit reached 540.32 million yuan, reflecting a year-on-year growth of 7.06%[38] - The company achieved operating revenue of CNY 14,603.1 million in 2021, representing a year-on-year growth of 13.86%[44] Research and Development - Research and development expenses rose by 27.38% to CNY 175.9 million, reflecting increased investment in innovation[46] - The company has developed a new product pipeline focusing on 10 initial varieties based on classic formulas[34] - The company has established a smart monitoring system for medicinal herb planting, enhancing the quality control of raw materials[84] - The company is collaborating with external research institutions to promote the transformation of research results into practical applications[85] - R&D investment accounted for 2.19% of the company's operating revenue during the reporting period, which is lower than the industry average[92] Market and Competition - The company is facing intensified competition as the domestic pharmaceutical market shifts from a seller's market to a buyer's market[40] - The company is actively exploring international markets, particularly in response to the growing demand for traditional Chinese medicine abroad[40] - The company aims to enhance its product portfolio by focusing on clinically valuable and health-functional products, with plans for new product development and introduction[113] - The company is committed to a digital transformation strategy, aiming for standardized data management and integrated supply chain control[116] Corporate Governance - The company has a governance structure that includes independent directors and external supervisors, with no shareholding changes reported for the board members during the reporting period[130] - The company has a clear strategy for maintaining operational independence from its controlling shareholder, ensuring fair market transactions[127] - The company emphasizes the importance of legal compliance and governance, ensuring transparency in shareholder meetings and board operations[123] - The company has a structured process for appointing and electing board members, ensuring compliance with governance standards[145] Environmental Responsibility - The company’s wastewater discharge from its pharmaceutical plant totaled 299,900 tons, with no exceedances reported[174] - The company achieved a total carbon emission of 18,030 tons in 2020, a year-on-year reduction of 8.4%[181] - The company actively participated in carbon emission management and completed a carbon emission rights transaction of 10,000 tons in December 2021[182] - The company’s air pollution control facilities operated normally, with pollutant emissions meeting regulatory standards[176] Future Outlook - Future outlook suggests a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[134] - The company plans to enhance its investment and acquisition activities to strengthen its market position and optimize resource allocation[115] - The company plans to introduce at least three new products in the next quarter, targeting emerging health trends[134] - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[134]